Last Update 16 Mar 26

Fair value Increased 7.83%

CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing

The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth.

Analyst Commentary

Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.

Bullish Takeaways

Bullish analysts highlight a solid Q4 performance as a sign that management is executing against current expectations. They see this as a support for the recent price target increases.
The 2026 revenue guidance is described as above prior Street estimates. Even though the range is wide, bullish analysts view it as an indication that management is comfortable laying out a multi year outlook.
Some bullish analysts argue that many investors are staying on the sidelines until the final CMS LCD is resolved, and view the current share price as inexpensive relative to that overhang.
In their view, the stock is attractive even when factoring in different potential CMS outcomes, which they see as already reflected in current valuation.

Bearish Takeaways

Bearish analysts describe the current risk reward as less compelling now that the share price has returned to levels seen before the restrictive draft LCD from MolDX in July.
They stress that 2026 revenue and longer term growth are highly dependent on the eventual shape of the final LCD, which they see as a key source of uncertainty for the story.
Some bearish analysts caution that next year's numbers could end up too high if the final LCD is less favorable, which could pressure both growth expectations and valuation.
There is also concern that Q4 2025 volume could come in below the midpoint of management's guidance, which would raise questions around execution against current forecasts.

What's in the News

CareDx reported full-year 2026 revenue guidance of US$420 million to US$444 million, including an estimated six-month Medicare LCD impact of about US$7.5 million (Key Developments).
The company outlined expectations for fourth-quarter 2025 revenue of approximately US$108 million and full-year 2025 revenue of about US$380 million, with both figures described in the guidance as higher year over year (Key Developments).
CareDx announced pivotal clinical validation results for AlloHeme, an AI powered NGS based blood test to monitor relapse after allogeneic hematopoietic cell transplant in AML and MDS, with data from the ACROBAT study presented at the 2026 Tandem Meetings and commercial launch plans to be discussed on a February 12, 2026 investor webcast (Key Developments).
The company launched VANTx, an AI powered, cloud native clinical data and analytics platform built on Databricks and Llama 3, aimed at supporting transplant research and real world evidence generation across kidney, heart, lung, and liver transplant indications (Key Developments).
CareDx disclosed a shareholder derivative litigation settlement relating to the Edelman and Burns actions, with a final approval hearing scheduled for June 30, 2026, in the U.S. District Court for the Northern District of California (Key Developments).

Valuation Changes

Fair Value: Adjusted from $23.00 to $24.80, representing a modest upward reset in the analyst model.
Discount Rate: Shifted slightly from 7.08% to 7.09%, indicating a very small change in the assumed risk profile.
Revenue Growth: Moved from 13.24% to 12.46%, reflecting a slightly lower assumed growth rate in the forward estimates.
Net Profit Margin: Updated from 9.15% to 9.56%, indicating a small improvement in expected profitability.
Future P/E: Trimmed from 24.35x to 24.17x, suggesting a marginally lower valuation multiple applied to future earnings.

0 views

Key Takeaways

Growing demand for core testing services and expansion into AI-driven diagnostics and digital health are driving recurring, high-margin revenue and supporting improved earnings stability.
Enhanced payer coverage and operational efficiencies position CareDx for sustained profitability and margin expansion through diversified revenue streams and lower operating costs.
Shifting reimbursement policies, regulatory uncertainties, and operational risks threaten revenue stability, margins, and the scalability of CareDx's core product-driven business model.

Catalysts

About CareDx

Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The steady double-digit growth in testing volumes, particularly with the expansion of surveillance protocols for kidney, heart, and lung transplants, suggests ongoing market penetration and growing demand for CareDx's core testing services-reflecting the global rise in organ transplants and chronic disease, which is likely to drive future revenue and topline growth.
The launch of AI-driven diagnostics like AlloSure Plus and integration into electronic health record systems (e.g., EPIC), positions CareDx to benefit from the broader adoption of precision medicine and personalized diagnostics, likely boosting adoption rates, aiding reimbursement, and ultimately supporting net margin improvements.
Significant progress in payer coverage-including millions of new covered lives, expanded in-network status, and the implementation of a unique CPT code for AlloSure-indicates a catalyst for sustained increases in ASP (average selling price) and recurring revenue streams, which can directly enhance future profitability and margin expansion.
Expansion of Patient & Digital Solutions and rapid growth in areas such as transplant pharmacy, remote patient monitoring, and digital health software reflects successful diversification of revenue streams tied to healthcare digitization, likely driving high-margin recurring revenues and supporting improved earnings stability.
Ongoing improvements in operational efficiency-including advancements in revenue cycle management, enhanced claim verification processes, and reduction in claims rejection rates-are expected to further lower operating costs relative to revenue, supporting improved EBITDA, better cash flow, and ultimately, higher net margins.

CareDx Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming CareDx's revenue will grow by 12.5% annually over the next 3 years.
Analysts are not forecasting that CareDx will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate CareDx's profit margin will increase from 17.1% to the average US Biotechs industry of 16.1% in 3 years.
If CareDx's profit margin were to converge on the industry average, you could expect earnings to reach $78.0 million (and earnings per share of $1.5) by about September 2028, up from $58.1 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 17.7x on those 2028 earnings, up from 11.7x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to decline by 0.76% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

CareDx Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Introduction of bundled payments and frequency limits for surveillance testing under the new draft LCD policy could potentially result in an annual revenue headwind of $15–30 million, directly impacting revenue growth and net margins if finalized as currently proposed.
Heavy reliance on AlloSure and HeartCare product lines means that any decrease in reimbursement or test volumes due to regulatory or payer changes could significantly compress earnings and threaten long-term profitability.
Continued uncertainty and potential downward adjustments in Medicare coverage and reimbursement for molecular diagnostic tests represent an enduring risk, as payers seek to control costs amidst industry-wide shifts toward bundled payments and value-based care, which may shrink the company's addressable market and revenues.
The transition in CFO leadership and possible operational execution risks (such as delays in EPIC integration and scaling digital health rollouts) may disrupt operational momentum and adversely affect margins, cash flow, or long-term scalability if not effectively managed.
Increased regulatory scrutiny (e.g., around billing, Medicare compliance, or LCD interpretations) and ongoing exposure to one-time revenue write-offs (such as the $3.8 million adjustment this quarter) indicate potential risks of higher SG&A costs, impacting net margins and forward earnings consistency.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $21.833 for CareDx based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $28.0, and the most bearish reporting a price target of just $14.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $485.8 million, earnings will come to $78.0 million, and it would be trading on a PE ratio of 17.7x, assuming you use a discount rate of 6.8%.
Given the current share price of $12.73, the analyst price target of $21.83 is 41.7% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on CareDx?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Rising Organ Transplant Demand And AI Diagnostics Will Create Opportunity